The current nomenclature for cardiorenal syndrome is problematic owing to its chronological approach and the systemic nature of some of the subtypes. We suggest adoption of a new concept, chronic cardiovascular–kidney disorder, that better reflects the contributions of common risk factors and shared pathophysiological mechanisms.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
08 January 2024
A Correction to this paper has been published: https://doi.org/10.1038/s41581-024-00805-5
References
Ronco, C., Haapio, M., House, A. A., Anavekar, N. & Bellomo, R. Cardiorenal syndrome. J. Am. Coll. Cardiol. 52, 1527–1539 (2008).
Jager, K. J. et al. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int. 96, 1048–1050 (2019).
Halimi, J. M. et al. Long-term impact of cardiorenal syndromes on major outcomes based on their chronology: a comprehensive French nationwide cohort study. Nephrol. Dial. Transplant. 37, 2386–2397 (2022).
Xu, Y. et al. Associations between long-term exposure to low-level air pollution and risk of chronic kidney disease-findings from the Malmö Diet and Cancer cohort. Environ. Int. 160, 107085 (2022).
Zoccali, C. & Mallamaci, F. Innate immunity system in patients with cardiovascular and kidney disease. Circ. Res. 132, 915–932 (2023).
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. Suppl. 3, 1–150 (2013).
Visseren, F. L. J. et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J. 42, 3227–3337 (2021).
van der Aart-van der Beek, A. B., de Boer, R. A. & Heerspink, H. J. L. Kidney and heart failure outcomes associated with SGLT2 inhibitor use. Nat. Rev. Nephrol. 18, 294–306 (2022).
Patel, R. B. et al. Challenges of cardio-kidney composite outcomes in large-scale clinical trials. Circulation 143, 949–958 (2021).
Pocock, S. J., Ariti, C. A., Collier, T. J. & Wang, D. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur. Heart J. 33, 176–182 (2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Zoccali, C., Mallamaci, F., Halimi, JM. et al. Chronic cardiovascular–kidney disorder: a new conceptual framework. Nat Rev Nephrol 20, 201–202 (2024). https://doi.org/10.1038/s41581-023-00789-8
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41581-023-00789-8